Colorectal Cancer Treatment Concepts for Internal Me... \| MDster                                                show = false, 1500)" role="region" aria-label="Connection status" aria-atomic="true" x-bind:aria-live="offline ? 'assertive' : 'polite'" x-bind:aria-hidden="(!show).toString()" class="offline-banner max-w-sm mx-auto px-4 py-3 text-sm font-bold text-center text-white rounded-full shadow-lg transition-all duration-500 ease-in-out" :class="{ 'hidden-state': !show, 'bg-error': offline, 'bg-success': !offline }"&gt;      You are offline 

     Back online! 

  [  MDster home ](/ "MDster home") 

  Specialities     [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics &amp; Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) 

 [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) 

 Menu      

  Specialities     [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Neurology ](https://mdster.com/speciality/neurology) [ Obstetrics &amp; Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) 

 [ Features ](https://mdster.com/features) [ SOE Examiner NEW ](https://mdster.com/soe-examiner) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) 

 [     Login    ](https://mdster.com/auth/login) 

 1. [        Home  ](https://mdster.com)
2. [   Blog  ](https://mdster.com/blog)
3. [   Medical Education  ](https://mdster.com/blog?category=medical-education)
4. Colorectal Cancer Treatment Concepts: Surgery to Surveillance

  [ Medical Education ](https://mdster.com/blog?category=medical-education)  

 Colorectal Cancer Treatment Concepts: Surgery to Surveillance 
===============================================================

 A board-focused, clinically practical review of how to think about surgery, adjuvant therapy, metastatic palliation, and post-resection follow-up in colorectal cancer.

  [     MDster Editorial Team ](https://mdster.com/about) ·      Mar 29, 2026  ·      6 min read  ·       390  

  [     Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) \| [Corrections Policy](https://mdster.com/corrections) 

    [ Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ Gastrointestinal Oncology ](https://mdster.com/blog?tag=gastrointestinal-oncology) [ Colorectal Cancer ](https://mdster.com/blog?tag=colorectal-cancer) [ Oncology Boards ](https://mdster.com/blog?tag=oncology-boards) [ Cancer Surveillance ](https://mdster.com/blog?tag=cancer-surveillance)  

                                                          ![Colorectal Cancer Treatment Concepts: Surgery to Surveillance](https://mdster.com/storage/blog/images/colorectal-cancer-treatment-concepts-surgery-to-surveillance.jpg)  

    Share this article 

        Share this post 

 On this page

 1. [ Start with treatment intent ](#start-with-treatment-intent)
2. [ Surgery and adjuvant therapy overview ](#surgery-and-adjuvant-therapy-overview)
3. [ Metastatic disease: palliative does not mean passive ](#metastatic-disease-palliative-does-not-mean-passive)
4. [ Surveillance after resection concepts ](#surveillance-after-resection-concepts)
5. [ Key Takeaways ](#key-takeaways)
6. [ Conclusion ](#conclusion)
7. [ References ](#references-heading)

 On this page

 1. [ Start with treatment intent ](#start-with-treatment-intent)
2. [ Surgery and adjuvant therapy overview ](#surgery-and-adjuvant-therapy-overview)
3. [ Metastatic disease: palliative does not mean passive ](#metastatic-disease-palliative-does-not-mean-passive)
4. [ Surveillance after resection concepts ](#surveillance-after-resection-concepts)
5. [ Key Takeaways ](#key-takeaways)
6. [ Conclusion ](#conclusion)
7. [ References ](#references-heading)

A patient with newly resected pT3N1 colon adenocarcinoma is recovering well, and the intern asks, “So we just watch now?” That question captures why **treatment concepts** matter. In colorectal cancer (CRC), the key decisions after diagnosis are not semantic; they define whether you are aiming for cure, relapse reduction, or palliation. For internists, this is everyday medicine: you will manage chemotherapy toxicity, iron deficiency, ostomy complications, VTE risk, and the surveillance plan long after the operation note is signed. [\[1\]](#cite-1 "Reference &#91;1&#93;")

Start with treatment intent
---------------------------

The first treatment question is not “colon or rectum?” It is **localized, potentially curable metastatic, or unresectable metastatic**. Localized **colon** cancer is usually surgery first. **Rectal** cancer is different: MRI staging drives management, and many higher-risk stage II/III cases now receive **total neoadjuvant therapy (TNT)** before any operation; selected complete responders may even discuss nonoperative management in expert programs. Always get **MMR/MSI status** early. That is not just genetics housekeeping: it helps identify Lynch syndrome and now directly changes treatment selection in rectal and metastatic disease. [\[2\]](#cite-2 "Reference &#91;2&#93;")

SettingUsual backboneBoard trap**Colon cancer**Surgery first, then adjuvant therapy by pathologic riskForgetting that node count matters for staging**Rectal cancer**MRI-based planning; neoadjuvant/TNT common in locally advanced diseaseTreating it like “colon cancer lower down”

That split is the one boards expect you to keep straight. [\[3\]](#cite-3 "Reference &#91;3&#93;")

Surgery and adjuvant therapy overview
-------------------------------------

For **colon cancer**, oncologic resection with adequate lymphadenectomy is the backbone, and **fewer than 12 lymph nodes examined** is itself a high-risk feature because it weakens staging confidence. **Stage III colon cancer** generally gets adjuvant chemotherapy unless frailty or competing risk overwhelms benefit; common platforms are **FOLFOX** or **CAPOX**, with duration individualized to recurrence risk and oxaliplatin neurotoxicity. **Stage II** is where learners overcall treatment. Do **not** give adjuvant therapy reflexively. Offer it clearly for **T4** tumors and consider it for other high-risk features such as fewer than 12 nodes, lymphovascular or perineural invasion, poor differentiation, obstruction, perforation, or marked tumor budding. The high-yield exception is **dMMR/MSI-H stage II disease**: do not routinely reach for fluoropyrimidine monotherapy there. [\[3\]](#cite-3 "Reference &#91;3&#93;")

Hereditary syndromes belong in this discussion, even in an overview. If Lynch syndrome, FAP, or another inherited syndrome is suspected, do not treat surgery as a one-size-fits-all event. The extent of colectomy, surveillance of the remaining bowel, and cascade testing for relatives may all change. In practice, that means the internist should not ignore a young patient, synchronous tumors, heavy family history, or universal tumor testing that shows MMR deficiency. [\[4\]](#cite-4 "Reference &#91;4&#93;")

> **Clinical Pearl:** In stage II colon cancer, the right question is not “chemo or no chemo?” It is “**which risk features are actually present, and is the tumor dMMR/MSI-H?**” That single pause prevents a lot of board errors. [\[3\]](#cite-3 "Reference &#91;3&#93;")

Metastatic disease: palliative does not mean passive
----------------------------------------------------

Most metastatic CRC is treated with **palliative intent**, but never confuse palliative with nihilistic. The goals are to control symptoms, preserve performance status, prolong survival, and keep future lines open. For **initially unresectable** disease, first-line therapy is usually a **doublet**, with triplet therapy reserved for select fit patients. Biology then takes over: **MSI-H/dMMR metastatic CRC** belongs in the immunotherapy lane; **left-sided, RAS wild-type, MSS/pMMR** disease often favors chemotherapy plus an **anti-EGFR** agent; **right-sided** RAS wild-type disease more often pairs chemotherapy with **anti-VEGF** therapy. In previously treated disease, know the board pairings: **BRAF V600E** disease points to **encorafenib plus cetuximab**, and **KRAS G12C** disease now has approved anti-EGFR-based targeted combinations in refractory settings. Limited liver, lung, or selected peritoneal metastases deserve multidisciplinary review because some patients can still reach **curative-intent resection or ablative therapy**. [\[5\]](#cite-5 "Reference &#91;5&#93;")

Do not wait until the last admission to involve palliative care. ASCO’s current guidance is clear: patients with advanced cancer should have **early specialty palliative care integrated alongside active oncologic treatment**, especially when symptoms, distress, or goals-of-care uncertainty are already present. That is good oncology and good internal medicine. [\[6\]](#cite-6 "Reference &#91;6&#93;")

Surveillance after resection concepts
-------------------------------------

Surveillance after curative-intent resection is not clerical follow-up; it is part of treatment. The aim is to detect **salvageable recurrence** and **metachronous neoplasia** while the patient still has options. A common framework is front-loaded follow-up for five years: history/physical and **CEA** at regular intervals early on, periodic **CT chest/abdomen/pelvis**, and **colonoscopy at 1 year** after surgery (or after the perioperative clearing exam), then usually at **3 years** and then every **5 years** if normal. Rectal cancer may need additional local surveillance depending on surgical technique and local recurrence risk. Two exam traps matter: do **not** substitute **FIT/fecal DNA** for post-resection surveillance, and do not order routine blood panels as if they are validated recurrence tests. Keep the program purposeful. [\[7\]](#cite-7 "Reference &#91;7&#93;")

Key Takeaways
-------------

- Classify CRC by **treatment intent** first: localized, potentially curable metastatic, or unresectable metastatic. [\[2\]](#cite-2 "Reference &#91;2&#93;")
- **Stage III colon cancer** usually gets adjuvant chemotherapy; **stage II** gets it selectively, and **dMMR/MSI-H stage II** is the classic exception. [\[3\]](#cite-3 "Reference &#91;3&#93;")
- **Rectal cancer is not colon cancer in a tighter space**; TNT now shapes many locally advanced rectal cases. [\[2\]](#cite-2 "Reference &#91;2&#93;")
- In metastatic disease, choose therapy by **MMR/MSI, RAS/BRAF status, sidedness, symptoms, and resectability**. [\[5\]](#cite-5 "Reference &#91;5&#93;")
- After curative resection, remember the surveillance spine: **CEA/exam, periodic CT, colonoscopy at 1 year, then 3 years, then 5 years if normal**. [\[7\]](#cite-7 "Reference &#91;7&#93;")

Conclusion
----------

If you remember one framework, make it this: **surgery treats the anatomy, adjuvant therapy treats microscopic risk, metastatic therapy follows tumor biology, and surveillance is active care—not an afterthought**. That mindset is high-yield for boards and safer for patients. [\[3\]](#cite-3 "Reference &#91;3&#93;")

 References  (8)  
------------------

 1. 1.  [ National Cancer Institute. Colon Cancer Treatment (PDQ®)–Health Professional Version.     ](https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq)   [↩](#cite-ref-1-1 "Back to text")
2. 2.  [ Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024.     ](https://pubmed.ncbi.nlm.nih.gov/39116386/)   [↩](#cite-ref-2-1 "Back to text")
3. 3.  [ Baxter NN, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022.     ](https://pubmed.ncbi.nlm.nih.gov/34936379/)   [↩](#cite-ref-3-1 "Back to text")
4. 4.  [ pubmed.ncbi.nlm.nih.gov/25452455     ](https://pubmed.ncbi.nlm.nih.gov/25452455/)   [↩](#cite-ref-4-1 "Back to text")
5. 5.  [ Morris VK, et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J Clin Oncol. 2023.     ](https://pubmed.ncbi.nlm.nih.gov/36252154/)   [↩](#cite-ref-5-1 "Back to text")
6. 6.  [ Ferrell BR, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024.     ](https://pubmed.ncbi.nlm.nih.gov/38748941/)   [↩](#cite-ref-6-1 "Back to text")
7. 7.  [ www.cancercareontario.ca/sites/ccocancercare/files/derivative/SurvivorshipClinicalGuidanceCRC.pdf     ](https://www.cancercareontario.ca/sites/ccocancercare/files/derivative/SurvivorshipClinicalGuidanceCRC.pdf)   [↩](#cite-ref-7-1 "Back to text")
8. 8.  [ American Gastroenterological Association. Colonoscopy surveillance after colorectal cancer resection.     ](https://gastro.org/clinical-guidance/colonoscopy-surveillance-after-colorectal-cancer-resection/)

Next

 Turn reading into Internal Medicine performance 
-------------------------------------------------

 - System‑based, exam‑style questions + explanations
- Smarter review to reinforce weak topics
- Build confidence with measurable progress

 [     Start practicing ](https://mdster.com/user/dashboard)  [     Internal Medicine ](https://mdster.com/speciality/internal-medicine)  

   [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features)  

 No credit card required. Full access to all features\*. No commitment. Cancel anytime.

 \*AI SOE Examiner is limited to 10 cases monthly for Advanced &amp; Bundle subscribers.

   Explore topics:  [ # Internal Medicine ](https://mdster.com/blog?tag=internal-medicine) [ # Gastrointestinal Oncology ](https://mdster.com/blog?tag=gastrointestinal-oncology) [ # Colorectal Cancer ](https://mdster.com/blog?tag=colorectal-cancer) [ # Oncology Boards ](https://mdster.com/blog?tag=oncology-boards) [ # Cancer Surveillance ](https://mdster.com/blog?tag=cancer-surveillance)  

  [     Back to all posts ](https://mdster.com/blog) 

 Discussion  ()  
-----------------

 Join the discussion

 [     Log in ](https://mdster.com/auth/login) or [     Sign up ](https://mdster.com/auth/register) 

No comments yet

Be the first to share your thoughts!

    ![]()     

More in Medical Education
-------------------------

 [ See all     ](https://mdster.com/blog?category=medical-education) 

  [###  Pediatric IgA Nephropathy and IgA Vasculitis Nephritis: Key Clues 

      6 min read       Nov 19, 2026

     ](https://mdster.com/blog/pediatric-iga-nephropathy-and-iga-vasculitis-nephritis-key-clues) [###  Reference Ranges and Pregnancy-Adjusted Labs: Avoiding Clinical Traps 

      2 min read       Nov 18, 2026

     ](https://mdster.com/blog/reference-ranges-and-pregnancy-adjusted-labs-avoiding-clinical-traps) [###  Inflammatory and Cardiac Biomarkers: Interpret Results in Context 

      5 min read       Nov 17, 2026

     ](https://mdster.com/blog/inflammatory-and-cardiac-biomarkers-interpret-results-in-context)  

Related Posts
-------------

  [                                ![Pediatric IgA Nephropathy and IgA Vasculitis Nephritis: Key Clues](https://mdster.com/storage/blog/images/pediatric-iga-nephropathy-and-iga-vasculitis-nephritis-key-clues.png)         Medical Education 

###  Pediatric IgA Nephropathy and IgA Vasculitis Nephritis: Key Clues 

 A child has dark urine during a sore throat—or purpura with abdominal pain. Learn how to recognize IgA-related nephritis, monitor kidney risk, and refer promptly.

     6 min read 

     0 comments 

 ](https://mdster.com/blog/pediatric-iga-nephropathy-and-iga-vasculitis-nephritis-key-clues) [                                ![Reference Ranges and Pregnancy-Adjusted Labs: Avoiding Clinical Traps](https://mdster.com/storage/blog/images/reference-ranges-and-pregnancy-adjusted-labs-avoiding-clinical-traps.png)         Medical Education 

###  Reference Ranges and Pregnancy-Adjusted Labs: Avoiding Clinical Traps 

 A lab result can look reassuring—or alarming—for the wrong reason in pregnancy. Learn which reference ranges change, which thresholds matter, and when symptoms override the number.

     2 min read 

     0 comments 

 ](https://mdster.com/blog/reference-ranges-and-pregnancy-adjusted-labs-avoiding-clinical-traps) [                                ![Inflammatory and Cardiac Biomarkers: Interpret Results in Context](https://mdster.com/storage/blog/images/inflammatory-and-cardiac-biomarkers-interpret-results-in-context.png)         Medical Education 

###  Inflammatory and Cardiac Biomarkers: Interpret Results in Context 

 An elevated biomarker is a clue, not a diagnosis. Learn how pretest probability, serial troponins, and imaging clarify uncertain inflammatory and cardiac presentations.

     5 min read 

     0 comments 

 ](https://mdster.com/blog/inflammatory-and-cardiac-biomarkers-interpret-results-in-context) [                                ![Identifying Ethical Dilemmas in Internal Medicine: When to Consult](https://mdster.com/storage/blog/images/identifying-ethical-dilemmas-in-internal-medicine-when-to-consult.png)         Medical Education 

###  Identifying Ethical Dilemmas in Internal Medicine: When to Consult 

 A patient may survive dialysis yet face burdens they would never have accepted. Learn to identify the uncertainty, capacity questions, and value conflicts that warrant ethics input.

     5 min read 

     0 comments 

 ](https://mdster.com/blog/identifying-ethical-dilemmas-in-internal-medicine-when-to-consult) [                                ![FAOD Clinical Presentation: Recognizing Hypoketotic Hypoglycemia](https://mdster.com/storage/blog/images/faod-clinical-presentation-recognizing-hypoketotic-hypoglycemia.png)         Medical Education 

###  FAOD Clinical Presentation: Recognizing Hypoketotic Hypoglycemia 

 Learn to recognize hypoketotic hypoglycemia in pediatric FAODs, distinguish MCAD from long-chain disease, and act before cardiac or muscle injury progresses.

     6 min read 

     0 comments 

 ](https://mdster.com/blog/faod-clinical-presentation-recognizing-hypoketotic-hypoglycemia) [                                ![PCOS and Metabolic Syndrome: Advanced Management Before Pregnancy](https://mdster.com/storage/blog/images/pcos-and-metabolic-syndrome-advanced-management-before-pregnancy.png)         Medical Education 

###  PCOS and Metabolic Syndrome: Advanced Management Before Pregnancy 

 A patient with PCOS needs more than ovulation induction. Learn how to assess metabolic risk, sequence fertility treatment, and plan pregnancy surveillance.

     6 min read 

     0 comments 

 ](https://mdster.com/blog/pcos-and-metabolic-syndrome-advanced-management-before-pregnancy)  

  [  MDster home ](/ "MDster home")

 Master your medical exams with evidence-based learning.

 [    Download on the App Store 

 ](https://apps.apple.com/app/id6759168258) [       GET IT ON Google Play 

 ](https://play.google.com/store/apps/details?id=com.mdster.app) 

Platform

- [Home](https://mdster.com)
- [Features](https://mdster.com/features)
- [Pricing](https://mdster.com/pricing)
- [About](https://mdster.com/about)

Resources

- [Blog](https://mdster.com/blog)
- [Curriculum](https://mdster.com/curriculum)
- [Claude &amp; ChatGPT](https://mdster.com/ai-assistants)
- [Dashboard](https://mdster.com/user/dashboard)

Support

- [Contact](https://mdster.com/contact)
- [Legal &amp; Policies](https://mdster.com/legal)
- [Medical Reviewers](https://mdster.com/medical-reviewers)

 © 2026 MDster

  [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy)  [    ](https://apps.apple.com/app/id6759168258) [    ](https://play.google.com/store/apps/details?id=com.mdster.app) 

     reCAPTCHA 

 Protected by reCAPTCHA.

 Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply.

Cookie Consent
--------------

 We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) &amp; [ Privacy Policy ](https://mdster.com/privacy)

  Accept
